Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.
de Vos, S
AffiliationOhio State University Comprehensive Cancer Center, Columbus
MetadataShow full item record
AbstractIn patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL), a short duration of response to therapy or adverse cytogenetic abnormalities are associated with a poor outcome. We evaluated the efficacy of ibrutinib, a covalent inhibitor of Bruton's tyrosine kinase, in patients at risk for a poor outcome.
CitationIbrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. 2014, 371 (3):213-23 N Engl J Med
JournalThe New England Journal of Medicine